A Study to Compare Two Formulations of LY3819469 in Healthy Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

27 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-30

Study Completion Date

2023-11-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to assess two formulations of LY3819469 based on the amount that gets into the blood stream and how long it takes the body to get rid of it, when given to healthy participants. The information about any adverse effects experienced will be collected and the tolerability of LY3819469 will also be evaluated.

Screening is required within 28 days prior to the enrolment. For each participant, the total duration of the clinical trial will be about 17 weeks including screening and follow-up periods.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of LY3493269 in Healthy Participants

NCT04682106

Healthy

COMPLETED PHASE1

A Study of LY3819469 in Healthy Participants

NCT04914546

Healthy

COMPLETED PHASE1

A Study of Two Different Formulations of LY3502970 in Healthy Participants

NCT05341089

Healthy

COMPLETED PHASE1

A Safety Study of LY3493269 Given as a Single Injection in Healthy Participants

NCT04178733

Healthy

COMPLETED PHASE1

A Multiple-Dose Study of LY3502970 in Healthy Participants

NCT05110794

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY3819469 (Reference)

LY3819469 administered subcutaneously (SC).

Group Type EXPERIMENTAL

LY3819469

Intervention Type DRUG

Administered SC.

LY3819469 (Test)

LY3819469 administered SC.

Group Type EXPERIMENTAL

LY3819469

Intervention Type DRUG

Administered SC.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY3819469

Administered SC.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female participants who are overtly healthy as determined by medical evaluation
* Have a body mass index (BMI) in the range of 18.5 to 35.0 kilogram per square meter (kg/m²), inclusive at the time of screening
* Are male or women not of childbearing potential

Exclusion Criteria

* Have a history or presence of an underlying disease, or surgical, physical, medical, or psychiatric condition that could affect interpretation of study data
* Have any abnormality in the 12-lead electrocardiogram (ECG)
* Are heavy alcohol drinkers or heavy cigarette smokers
* Have participated, within the last 30 days, in a clinical study involving an investigational product. If the previous investigational product has a long half-life, 5 half-lives, or 30 days, whichever is longer, should have passed prior to CRU admission
* Have lost or donated blood of more than 450 mililitres (mL) within 3 months

Minimum Eligible Age

21 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes